The Role of Cetuximab in the Induction of Anticancer Immune Response in Colorectal Cancer Treatment

被引：40
|
作者：
Holubec, Lubos [1 ,4 ]
Polivka, Jiri, Jr. [1 ,2 ]
Safanda, Martin [4 ]
Karas, Michal [3 ]
Liska, Vaclav [1 ]
机构：
[1] Charles Univ Prague, Biomed Ctr, Fac Med Plzen, Plzen, Czech Republic
[2] Charles Univ Prague, Dept Histol & Embryol, Fac Med Plzen, Plzen, Czech Republic
[3] Charles Univ Prague, Dept Hematol & Oncol, Fac Med Plzen, Plzen, Czech Republic
[4] Na Homolce Hosp, Dept Clin Oncol, Prague, Czech Republic
来源：
ANTICANCER RESEARCH | 2016年 / 36卷 / 09期
关键词：
Colorectal cancer; cetuximab; immune response; targeted therapy; immunomodulation; review; GAMMA RECEPTOR POLYMORPHISMS; CHECKPOINT INHIBITORS; MONOCLONAL-ANTIBODIES; THERAPY; EGFR; IMMUNOTHERAPY; PANITUMUMAB; SURVIVAL; MICROENVIRONMENT; CYTOTOXICITY;
D O I：
10.21873/anticanres.10985
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Monoclonal antibodies binding the epidermal growth factor receptor (EGFR), such as cetuximab or panitumumab, are widely used targeted therapeutics for the treatment of patients with colorectal cancer. The clinical significance of these drugs has so far been associated with combined chemotherapy or radiation. It has been shown that these treatment strategies have their clinical limitations and do not fully exploit the immunomodulatory effect of these drugs. In this review, we discuss the mechanisms of immunomodulation together with the anticancer immune response to the monoclonal antibodies targeted to the EGFR. The combination of anti-EGFR monoclonal antibodies with other immunotherapeutic treatment modalities certainly brings new opportunities for targeted therapy in patients with colorectal cancer.
引用
收藏
页码：4421 / 4426
页数：6
相关论文
共 50 条
  • [41] A Phase II Study of Capecitabine, Oxaliplatin, Bevacizumab and Cetuximab in the Treatment of Metastatic Colorectal Cancer
    Wong, Nan Soon
    Fernando, Nishan H.
    Nixon, Andrew B.
    Cushman, Stephanie
    Aklilu, Mebea
    Bendell, Johanna C.
    Morse, Michael A.
    Blobe, Gerard C.
    Ashton, Jill
    Pang, Herbert
    Hurwitz, Herbert I.
    ANTICANCER RESEARCH, 2011, 31 (01) : 255 - 261
  • [42] Mutational analysis of primary and metastatic colorectal cancer samples underlying the resistance to cetuximab-based therapy
    Nemecek, Radim
    Berkovcova, Jitka
    Radova, Lenka
    Kazda, Tomas
    Mlcochova, Jitka
    Vychytilova-Faltejskova, Petra
    Slaby, Ondrej
    Svoboda, Marek
    ONCOTARGETS AND THERAPY, 2016, 9 : 4695 - 4703
  • [43] The Role of HER-3 Expression in the Prediction of Clinical Outcome for Advanced Colorectal Cancer Patients Receiving Irinotecan and Cetuximab
    Scartozzi, Mario
    Mandolesi, Alessandra
    Giampieri, Riccardo
    Bittoni, Alessandro
    Pierantoni, Chiara
    Zaniboni, Alberto
    Galizia, Eva
    Giustini, Lucio
    Silva, Rosa Rita
    Bisonni, Renato
    Berardi, Rossana
    Biscotti, Tommasina
    Biagetti, Simona
    Bearzi, Italo
    Cascinu, Stefano
    ONCOLOGIST, 2011, 16 (01) : 53 - 60
  • [44] Cetuximab in metastatic colorectal cancer
    Broadbridge, Vy Tuong
    Karapetis, Cristos S.
    Price, Timothy Jay
    EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (05) : 555 - 565
  • [45] Cetuximab intensifies the ADCC activity of adoptive NK cells in a nude mouse colorectal cancer xenograft model
    Chen, Shanshan
    Li, Xuechun
    Chen, Rongming
    Yin, Mingang
    Zheng, Qiuhong
    ONCOLOGY LETTERS, 2016, 12 (03) : 1868 - 1876
  • [46] PET detection of epidermal growth factor receptor in colorectal cancer: a real predictor of response to cetuximab treatment?
    M. A. Pantaleo
    S. Fanti
    P. L. Lollini
    S. Boschi
    G. Biasco
    European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34 : 1510 - 1511
  • [47] Meta-analysis of the predictive value of KRAS mutations in treatment response using cetuximab in colorectal cancer
    Tsoukalas, N.
    Tzovaras, A. A.
    Tolia, M.
    Kostakis, I. D.
    Papakostidi, A.
    Pistamaltzian, N.
    Ardavanis, A.
    JOURNAL OF BUON, 2012, 17 (01): : 73 - 78
  • [48] Standard chemotherapy with cetuximab for treatment of colorectal cancer
    Xin-Xiang Li
    Lei Liang
    Li-Yong Huang
    San-Jun Cai
    World Journal of Gastroenterology, 2015, (22) : 7022 - 7035
  • [49] Cetuximab in the management of colorectal cancer
    Lenz, Heinz-Josef
    BIOLOGICS-TARGETS & THERAPY, 2007, 1 (02) : 77 - 91
  • [50] The role of salvage treatment in advanced colorectal cancer
    Capdevila, Jaume
    Javier Ramos, Francisco
    Macarulla, Teresa
    Elez, Elena
    Tabernero, Josep
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2009, 71 (01) : 53 - 61
12345